Related Experiment Videos
Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules
Medical and Pediatric Oncology
|January 1, 1976
Summary
This study compared Mitomycin-C and Porfiromycin for disseminated gastrointestinal cancers. Both drugs showed similar partial remission rates, but Porfiromycin had more cumulative toxicity, suggesting further Mitomycin-C trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- Disseminated gastrointestinal cancers present significant treatment challenges.
- Mitomycin-C and Porfiromycin are chemotherapeutic agents with potential efficacy.
Purpose of the Study:
- To compare the efficacy and toxicity of Mitomycin-C and Porfiromycin in patients with disseminated abdominal adenocarcinoma.
- To evaluate treatment response based on tumor type.
Main Methods:
- A randomized prospective study involving 63 patients with disseminated gastrointestinal or abdominal adenocarcinoma.
- Patients received either Mitomycin-C (22.5 mg/M2) or Porfiromycin (75 mg/M2) via intravenous bolus every 6-8 weeks.
- Tumor response and toxicity (myelosuppression) were assessed.
Main Results:
- Partial remission rates were 34% for Mitomycin-C (11/32 patients) and 32% for Porfiromycin (10/31 patients).
- Responses varied by tumor type, with notable activity in ovarian and upper GI cancers for both agents.
- Both drugs caused significant myelosuppression, with Porfiromycin exhibiting more cumulative toxicity.
Conclusions:
- Mitomycin-C and Porfiromycin demonstrate comparable partial remission rates in disseminated abdominal adenocarcinomas.
- Porfiromycin's cumulative toxicity warrants careful consideration.
- Further clinical investigation of Mitomycin-C on an acute intermittent bolus schedule is justified.